Patrick Johnston
Concepts (729)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 59 | 2026 | 192 | 11.470 |
Why?
| | Lymphoma, Non-Hodgkin | 38 | 2026 | 124 | 6.930 |
Why?
| | Hematopoietic Stem Cell Transplantation | 35 | 2026 | 677 | 5.010 |
Why?
| | Visual Perception | 7 | 2025 | 182 | 3.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 47 | 2026 | 1961 | 3.120 |
Why?
| | Transplantation, Autologous | 34 | 2026 | 296 | 3.050 |
Why?
| | Lymphoma | 18 | 2024 | 233 | 2.660 |
Why?
| | Immunotherapy, Adoptive | 23 | 2026 | 339 | 2.460 |
Why?
| | Hodgkin Disease | 18 | 2026 | 171 | 2.360 |
Why?
| | Salvage Therapy | 13 | 2024 | 164 | 2.300 |
Why?
| | Lymphoma, B-Cell | 16 | 2026 | 134 | 2.250 |
Why?
| | Neoplasm Recurrence, Local | 25 | 2026 | 1145 | 2.140 |
Why?
| | Antigens, CD19 | 12 | 2024 | 129 | 2.130 |
Why?
| | Central Nervous System Neoplasms | 11 | 2026 | 175 | 2.120 |
Why?
| | Reaction Time | 6 | 2025 | 438 | 1.830 |
Why?
| | Visual Cortex | 2 | 2025 | 84 | 1.610 |
Why?
| | Rituximab | 28 | 2025 | 211 | 1.420 |
Why?
| | Lymphoma, Follicular | 13 | 2025 | 56 | 1.410 |
Why?
| | Biological Products | 9 | 2023 | 256 | 1.150 |
Why?
| | Aged | 122 | 2026 | 25955 | 1.140 |
Why?
| | Everolimus | 11 | 2018 | 112 | 1.040 |
Why?
| | Adult | 128 | 2026 | 40489 | 1.040 |
Why?
| | Middle Aged | 132 | 2026 | 35971 | 1.040 |
Why?
| | Humans | 235 | 2026 | 144667 | 1.000 |
Why?
| | Male | 152 | 2026 | 72431 | 0.940 |
Why?
| | Retrospective Studies | 63 | 2026 | 17149 | 0.930 |
Why?
| | Granulocyte Colony-Stimulating Factor | 5 | 2021 | 89 | 0.920 |
Why?
| | Aged, 80 and over | 61 | 2026 | 8284 | 0.910 |
Why?
| | Young Adult | 55 | 2026 | 14122 | 0.890 |
Why?
| | Lymphocytes | 9 | 2026 | 379 | 0.890 |
Why?
| | Evoked Potentials | 4 | 2025 | 127 | 0.870 |
Why?
| | Female | 145 | 2026 | 78304 | 0.860 |
Why?
| | Disease-Free Survival | 29 | 2023 | 768 | 0.800 |
Why?
| | Prognosis | 45 | 2026 | 4312 | 0.800 |
Why?
| | Monocytes | 9 | 2019 | 536 | 0.740 |
Why?
| | Antineoplastic Agents | 18 | 2021 | 2201 | 0.720 |
Why?
| | Photic Stimulation | 5 | 2025 | 264 | 0.710 |
Why?
| | Attention | 2 | 2025 | 458 | 0.700 |
Why?
| | Fluorodeoxyglucose F18 | 8 | 2024 | 161 | 0.690 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 10 | 2015 | 35 | 0.690 |
Why?
| | Waldenstrom Macroglobulinemia | 5 | 2023 | 20 | 0.690 |
Why?
| | Lymphocyte Count | 17 | 2022 | 164 | 0.690 |
Why?
| | Sirolimus | 6 | 2015 | 280 | 0.680 |
Why?
| | Recurrence | 17 | 2024 | 1136 | 0.670 |
Why?
| | Lymphoma, Mantle-Cell | 6 | 2022 | 33 | 0.660 |
Why?
| | Brain Mapping | 6 | 2022 | 535 | 0.660 |
Why?
| | Cyclophosphamide | 15 | 2025 | 265 | 0.650 |
Why?
| | Electroencephalography | 6 | 2025 | 555 | 0.650 |
Why?
| | Radiopharmaceuticals | 6 | 2021 | 206 | 0.630 |
Why?
| | Neurotoxicity Syndromes | 4 | 2023 | 40 | 0.590 |
Why?
| | Multiple Myeloma | 7 | 2023 | 306 | 0.590 |
Why?
| | Treatment Outcome | 41 | 2026 | 11735 | 0.580 |
Why?
| | Doxorubicin | 13 | 2025 | 398 | 0.560 |
Why?
| | Retinal Neoplasms | 5 | 2018 | 37 | 0.560 |
Why?
| | Vincristine | 11 | 2025 | 140 | 0.560 |
Why?
| | Retinal Detachment | 6 | 2009 | 73 | 0.550 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2021 | 76 | 0.550 |
Why?
| | Survival Rate | 21 | 2021 | 2089 | 0.530 |
Why?
| | Spatial Processing | 1 | 2017 | 1 | 0.510 |
Why?
| | Neoplasms, Second Primary | 2 | 2017 | 101 | 0.500 |
Why?
| | Time Perception | 1 | 2017 | 33 | 0.490 |
Why?
| | Prednisone | 10 | 2025 | 221 | 0.490 |
Why?
| | Positron-Emission Tomography | 7 | 2024 | 343 | 0.490 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 97 | 0.480 |
Why?
| | Combined Modality Therapy | 9 | 2024 | 1268 | 0.470 |
Why?
| | Brain | 7 | 2021 | 2934 | 0.470 |
Why?
| | Methotrexate | 4 | 2025 | 231 | 0.460 |
Why?
| | Transplantation Conditioning | 10 | 2015 | 186 | 0.450 |
Why?
| | Cell Transformation, Neoplastic | 5 | 2019 | 337 | 0.450 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 881 | 0.440 |
Why?
| | Face | 1 | 2016 | 174 | 0.440 |
Why?
| | Stem Cell Transplantation | 7 | 2021 | 190 | 0.440 |
Why?
| | Antibodies, Monoclonal | 9 | 2017 | 1505 | 0.430 |
Why?
| | Vitreous Body | 7 | 2018 | 117 | 0.430 |
Why?
| | Piperidines | 5 | 2022 | 219 | 0.420 |
Why?
| | Survival Analysis | 19 | 2021 | 1370 | 0.410 |
Why?
| | Autografts | 6 | 2022 | 55 | 0.410 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2021 | 201 | 0.410 |
Why?
| | Follow-Up Studies | 24 | 2025 | 5414 | 0.400 |
Why?
| | Synovial Cyst | 1 | 2013 | 4 | 0.390 |
Why?
| | Positron Emission Tomography Computed Tomography | 4 | 2023 | 117 | 0.380 |
Why?
| | Amyloidosis | 4 | 2018 | 44 | 0.370 |
Why?
| | Pyrimidines | 6 | 2025 | 519 | 0.360 |
Why?
| | Antigens, CD20 | 5 | 2017 | 34 | 0.360 |
Why?
| | Wrist | 1 | 2013 | 60 | 0.360 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 3 | 2022 | 19 | 0.360 |
Why?
| | Fingers | 1 | 2013 | 107 | 0.360 |
Why?
| | Pyrazoles | 5 | 2022 | 512 | 0.360 |
Why?
| | Radioimmunotherapy | 4 | 2017 | 25 | 0.350 |
Why?
| | Lymphoma, T-Cell | 3 | 2015 | 29 | 0.330 |
Why?
| | Eye Neoplasms | 5 | 2014 | 30 | 0.320 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2009 | 431 | 0.310 |
Why?
| | Adolescent | 34 | 2026 | 22409 | 0.310 |
Why?
| | Orthopedic Procedures | 1 | 2013 | 242 | 0.310 |
Why?
| | Lasers, Solid-State | 1 | 2009 | 22 | 0.290 |
Why?
| | Neoplasm Proteins | 4 | 2019 | 441 | 0.290 |
Why?
| | Burkitt Lymphoma | 3 | 2022 | 62 | 0.280 |
Why?
| | Neoplasm Staging | 12 | 2020 | 1465 | 0.280 |
Why?
| | Cataract Extraction | 2 | 2009 | 120 | 0.280 |
Why?
| | Molecular Targeted Therapy | 2 | 2010 | 437 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 10 | 2026 | 3888 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 12 | 2018 | 967 | 0.270 |
Why?
| | Risk Factors | 23 | 2022 | 10796 | 0.270 |
Why?
| | Thalidomide | 3 | 2018 | 43 | 0.260 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 4 | 2018 | 138 | 0.260 |
Why?
| | Killer Cells, Natural | 4 | 2023 | 470 | 0.260 |
Why?
| | Dexamethasone | 6 | 2022 | 366 | 0.250 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2012 | 27 | 0.250 |
Why?
| | Pattern Recognition, Visual | 2 | 2025 | 105 | 0.250 |
Why?
| | Lymphoma, T-Cell, Peripheral | 2 | 2024 | 20 | 0.240 |
Why?
| | Transfusion Reaction | 1 | 2006 | 61 | 0.240 |
Why?
| | Castleman Disease | 1 | 2026 | 16 | 0.240 |
Why?
| | TOR Serine-Threonine Kinases | 4 | 2017 | 452 | 0.240 |
Why?
| | Chemoradiotherapy | 2 | 2021 | 239 | 0.230 |
Why?
| | Fracture Fixation | 1 | 2006 | 79 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 45 | 0.230 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 631 | 0.230 |
Why?
| | Hip Fractures | 1 | 2006 | 86 | 0.230 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2025 | 19 | 0.230 |
Why?
| | Adaptation, Physiological | 2 | 2022 | 567 | 0.220 |
Why?
| | Event-Related Potentials, P300 | 1 | 2025 | 15 | 0.220 |
Why?
| | Eye Injuries | 3 | 1991 | 53 | 0.220 |
Why?
| | Central Nervous System | 3 | 2023 | 279 | 0.220 |
Why?
| | B-Lymphocytes | 6 | 2023 | 875 | 0.220 |
Why?
| | Thrombocytopenia | 3 | 2022 | 202 | 0.220 |
Why?
| | Medical Oncology | 2 | 2026 | 331 | 0.210 |
Why?
| | Skin Neoplasms | 2 | 2022 | 850 | 0.210 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2024 | 29 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 869 | 0.210 |
Why?
| | Perioperative Care | 1 | 2006 | 231 | 0.200 |
Why?
| | Appendicitis | 1 | 2026 | 150 | 0.200 |
Why?
| | Conditioning, Classical | 2 | 2022 | 119 | 0.200 |
Why?
| | Mediastinal Neoplasms | 1 | 2024 | 53 | 0.200 |
Why?
| | Cancer Vaccines | 1 | 2025 | 160 | 0.200 |
Why?
| | Hepatitis A | 1 | 2024 | 25 | 0.200 |
Why?
| | Multiprotein Complexes | 3 | 2017 | 171 | 0.200 |
Why?
| | Aqueous Humor | 2 | 2014 | 38 | 0.200 |
Why?
| | Incidence | 9 | 2024 | 2892 | 0.200 |
Why?
| | Fear | 2 | 2022 | 366 | 0.200 |
Why?
| | Orientation | 1 | 2023 | 50 | 0.190 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 2014 | 23 | 0.190 |
Why?
| | Hydroxamic Acids | 2 | 2014 | 94 | 0.190 |
Why?
| | Predictive Value of Tests | 11 | 2018 | 2117 | 0.190 |
Why?
| | Standard of Care | 4 | 2025 | 81 | 0.190 |
Why?
| | Prospective Studies | 15 | 2025 | 7994 | 0.190 |
Why?
| | Extinction, Psychological | 2 | 2022 | 91 | 0.190 |
Why?
| | Immunologic Factors | 3 | 2014 | 259 | 0.190 |
Why?
| | Venous Thromboembolism | 2 | 2022 | 326 | 0.190 |
Why?
| | Cell- and Tissue-Based Therapy | 4 | 2024 | 78 | 0.190 |
Why?
| | Cerebellum | 2 | 2017 | 224 | 0.190 |
Why?
| | Facial Expression | 1 | 2023 | 73 | 0.180 |
Why?
| | Vitamin D Deficiency | 2 | 2017 | 187 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2754 | 0.180 |
Why?
| | Yttrium Radioisotopes | 4 | 2017 | 64 | 0.180 |
Why?
| | Electromyography | 1 | 2024 | 416 | 0.180 |
Why?
| | Carmustine | 2 | 2020 | 52 | 0.180 |
Why?
| | Brain Diseases | 1 | 2023 | 152 | 0.180 |
Why?
| | Transcription Factors | 1 | 2010 | 1726 | 0.180 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2019 | 117 | 0.170 |
Why?
| | Bortezomib | 4 | 2018 | 54 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 3 | 2013 | 51 | 0.170 |
Why?
| | Cohort Studies | 13 | 2026 | 5957 | 0.170 |
Why?
| | Facial Recognition | 1 | 2022 | 35 | 0.170 |
Why?
| | Magnesium Deficiency | 1 | 2021 | 2 | 0.170 |
Why?
| | Central Nervous System Diseases | 1 | 2022 | 74 | 0.170 |
Why?
| | Status Epilepticus | 1 | 2022 | 68 | 0.170 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 27 | 0.170 |
Why?
| | Measles virus | 3 | 2010 | 21 | 0.170 |
Why?
| | Fluorine Radioisotopes | 1 | 2021 | 14 | 0.170 |
Why?
| | Immunoconjugates | 1 | 2022 | 138 | 0.170 |
Why?
| | Space Perception | 1 | 2021 | 82 | 0.160 |
Why?
| | Bacterial Infections | 1 | 2023 | 247 | 0.160 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 410 | 0.160 |
Why?
| | Magnesium | 1 | 2021 | 155 | 0.160 |
Why?
| | Vision, Ocular | 1 | 2020 | 47 | 0.160 |
Why?
| | Cytokines | 4 | 2021 | 2045 | 0.160 |
Why?
| | Schizophrenia | 2 | 2017 | 443 | 0.160 |
Why?
| | Antigens, CD34 | 2 | 2010 | 88 | 0.160 |
Why?
| | Testis | 1 | 2021 | 162 | 0.160 |
Why?
| | Medication Systems | 1 | 2000 | 3 | 0.160 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 73 | 0.160 |
Why?
| | Autoimmunity | 2 | 2018 | 930 | 0.160 |
Why?
| | Filgrastim | 2 | 2017 | 13 | 0.160 |
Why?
| | Heterocyclic Compounds | 2 | 2012 | 23 | 0.150 |
Why?
| | Retinal Perforations | 3 | 1996 | 18 | 0.150 |
Why?
| | Lymphopenia | 2 | 2010 | 64 | 0.150 |
Why?
| | Automation | 1 | 2000 | 104 | 0.150 |
Why?
| | Leukemia, B-Cell | 1 | 2019 | 12 | 0.150 |
Why?
| | Nursing Staff | 1 | 2000 | 40 | 0.150 |
Why?
| | Melphalan | 4 | 2017 | 43 | 0.150 |
Why?
| | Leg | 1 | 2021 | 240 | 0.150 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 779 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 638 | 0.150 |
Why?
| | Proportional Hazards Models | 7 | 2023 | 1322 | 0.150 |
Why?
| | Recombinant Proteins | 3 | 2017 | 1363 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 4 | 2019 | 971 | 0.150 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2010 | 41 | 0.150 |
Why?
| | Cues | 1 | 2021 | 326 | 0.140 |
Why?
| | Infusions, Parenteral | 1 | 2018 | 47 | 0.140 |
Why?
| | Time Factors | 12 | 2019 | 7140 | 0.140 |
Why?
| | Leukocyte Count | 3 | 2014 | 315 | 0.140 |
Why?
| | Vidarabine | 4 | 2017 | 32 | 0.140 |
Why?
| | Mental Recall | 1 | 2020 | 222 | 0.140 |
Why?
| | Janus Kinase 1 | 1 | 2018 | 26 | 0.140 |
Why?
| | Child | 16 | 2026 | 22600 | 0.140 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2019 | 70 | 0.140 |
Why?
| | Autistic Disorder | 2 | 2011 | 211 | 0.130 |
Why?
| | Mutation, Missense | 1 | 2019 | 338 | 0.130 |
Why?
| | Drug Approval | 2 | 2010 | 91 | 0.130 |
Why?
| | Thrombosis | 1 | 2022 | 396 | 0.130 |
Why?
| | Leukapheresis | 2 | 2016 | 27 | 0.130 |
Why?
| | Northern Ireland | 5 | 2009 | 12 | 0.130 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 108 | 0.130 |
Why?
| | Contingent Negative Variation | 1 | 2017 | 9 | 0.130 |
Why?
| | Immunoglobulin lambda-Chains | 2 | 2014 | 9 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2006 | 2950 | 0.130 |
Why?
| | Waste Disposal, Fluid | 1 | 2017 | 53 | 0.130 |
Why?
| | Immunotherapy | 2 | 2019 | 662 | 0.130 |
Why?
| | Delay Discounting | 1 | 2017 | 29 | 0.130 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2017 | 87 | 0.130 |
Why?
| | Visual Fields | 2 | 2017 | 116 | 0.130 |
Why?
| | Evoked Potentials, Visual | 1 | 2017 | 42 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2015 | 318 | 0.120 |
Why?
| | Fluorouracil | 2 | 2016 | 234 | 0.120 |
Why?
| | Maximum Tolerated Dose | 4 | 2019 | 211 | 0.120 |
Why?
| | Tarsal Coalition | 1 | 2016 | 1 | 0.120 |
Why?
| | Subtalar Joint | 1 | 2016 | 5 | 0.120 |
Why?
| | Evoked Potentials, Auditory | 1 | 2017 | 180 | 0.120 |
Why?
| | Magnetoencephalography | 1 | 2017 | 161 | 0.120 |
Why?
| | Visual Acuity | 4 | 1996 | 491 | 0.120 |
Why?
| | Glycine | 1 | 2017 | 186 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2021 | 3603 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2018 | 242 | 0.120 |
Why?
| | Mental Processes | 1 | 2015 | 38 | 0.110 |
Why?
| | Body Fluids | 1 | 1996 | 71 | 0.110 |
Why?
| | Uveitis | 2 | 2014 | 149 | 0.110 |
Why?
| | Biomarkers | 6 | 2023 | 4261 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2019 | 498 | 0.110 |
Why?
| | Odds Ratio | 4 | 2018 | 1076 | 0.110 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 147 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 214 | 0.110 |
Why?
| | Hemangioma, Capillary | 1 | 1995 | 14 | 0.110 |
Why?
| | Outpatients | 1 | 2018 | 447 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Immunoblastic | 1 | 2014 | 1 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 259 | 0.110 |
Why?
| | Comprehension | 1 | 2017 | 182 | 0.110 |
Why?
| | Folic Acid | 1 | 2016 | 198 | 0.110 |
Why?
| | United States | 6 | 2025 | 16018 | 0.110 |
Why?
| | Psychotic Disorders | 1 | 2017 | 185 | 0.110 |
Why?
| | Environmental Monitoring | 1 | 2017 | 374 | 0.110 |
Why?
| | Boronic Acids | 2 | 2014 | 36 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2017 | 652 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2013 | 310 | 0.110 |
Why?
| | Translocation, Genetic | 2 | 2022 | 118 | 0.100 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2015 | 59 | 0.100 |
Why?
| | Optic Disk | 1 | 1995 | 53 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 198 | 0.100 |
Why?
| | Water Pollutants, Chemical | 1 | 2017 | 229 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 331 | 0.100 |
Why?
| | Biomarkers, Tumor | 4 | 2013 | 1319 | 0.100 |
Why?
| | Neoplasms | 2 | 2022 | 2873 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2015 | 146 | 0.100 |
Why?
| | Pyrazines | 2 | 2014 | 92 | 0.100 |
Why?
| | Autoimmune Diseases | 2 | 2018 | 465 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2016 | 1103 | 0.100 |
Why?
| | Heart Atria | 1 | 2014 | 141 | 0.100 |
Why?
| | Polyneuropathies | 1 | 2013 | 57 | 0.100 |
Why?
| | Intestinal Neoplasms | 1 | 2013 | 30 | 0.100 |
Why?
| | Indoles | 2 | 2014 | 504 | 0.100 |
Why?
| | Intestinal Perforation | 1 | 2013 | 46 | 0.100 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 45 | 0.100 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2013 | 140 | 0.090 |
Why?
| | Retinal Neovascularization | 1 | 1993 | 28 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2008 | 341 | 0.090 |
Why?
| | Remission Induction | 4 | 2017 | 309 | 0.090 |
Why?
| | T-Lymphocytes | 3 | 2018 | 1984 | 0.090 |
Why?
| | POEMS Syndrome | 1 | 2012 | 3 | 0.090 |
Why?
| | Peripheral Nerves | 1 | 2013 | 71 | 0.090 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2014 | 264 | 0.090 |
Why?
| | Scleral Diseases | 1 | 1992 | 2 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1928 | 0.090 |
Why?
| | Hematologic Neoplasms | 2 | 2013 | 163 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2015 | 2489 | 0.090 |
Why?
| | Disease Progression | 6 | 2021 | 2847 | 0.090 |
Why?
| | Carbonated Beverages | 1 | 1991 | 16 | 0.090 |
Why?
| | Corneal Diseases | 1 | 1992 | 46 | 0.090 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 1992 | 41 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11790 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2000 | 1180 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2013 | 128 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1766 | 0.080 |
Why?
| | Sensitivity and Specificity | 4 | 2026 | 1995 | 0.080 |
Why?
| | Contrast Media | 2 | 2026 | 492 | 0.080 |
Why?
| | Stomach Neoplasms | 1 | 2013 | 130 | 0.080 |
Why?
| | Disease Management | 2 | 2026 | 650 | 0.080 |
Why?
| | Oncolytic Virotherapy | 1 | 2010 | 13 | 0.080 |
Why?
| | Blast Injuries | 1 | 1991 | 62 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 238 | 0.080 |
Why?
| | Oncolytic Viruses | 1 | 2010 | 8 | 0.080 |
Why?
| | Gene Targeting | 1 | 2010 | 80 | 0.080 |
Why?
| | Samarium | 1 | 2010 | 1 | 0.080 |
Why?
| | Myeloablative Agonists | 1 | 2010 | 23 | 0.080 |
Why?
| | Cornea | 1 | 1992 | 154 | 0.080 |
Why?
| | Radioisotopes | 1 | 2010 | 37 | 0.080 |
Why?
| | Arrhythmias, Cardiac | 1 | 2013 | 355 | 0.080 |
Why?
| | X-Ray Intensifying Screens | 1 | 2010 | 3 | 0.080 |
Why?
| | Miosis | 1 | 1990 | 4 | 0.080 |
Why?
| | Gray Matter | 1 | 2011 | 92 | 0.080 |
Why?
| | Self Report | 1 | 2015 | 869 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2015 | 834 | 0.080 |
Why?
| | Short Bowel Syndrome | 1 | 2010 | 27 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2014 | 1437 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 685 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 6041 | 0.080 |
Why?
| | Holidays | 1 | 2009 | 8 | 0.080 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2010 | 62 | 0.080 |
Why?
| | Indomethacin | 1 | 1990 | 76 | 0.080 |
Why?
| | Radiometry | 1 | 2010 | 56 | 0.080 |
Why?
| | Minnesota | 4 | 2013 | 170 | 0.080 |
Why?
| | Oxazines | 1 | 2009 | 37 | 0.080 |
Why?
| | Iris Diseases | 1 | 1989 | 7 | 0.080 |
Why?
| | Electronics | 1 | 2010 | 69 | 0.080 |
Why?
| | Interleukin-15 | 1 | 2010 | 96 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 26 | 0.080 |
Why?
| | Uveal Neoplasms | 1 | 1989 | 16 | 0.070 |
Why?
| | Pain Threshold | 1 | 2009 | 72 | 0.070 |
Why?
| | Severity of Illness Index | 4 | 2015 | 2922 | 0.070 |
Why?
| | Organophosphorus Compounds | 1 | 2010 | 84 | 0.070 |
Why?
| | Organometallic Compounds | 1 | 2010 | 113 | 0.070 |
Why?
| | Lenses, Intraocular | 1 | 1989 | 49 | 0.070 |
Why?
| | Quinolones | 1 | 2011 | 202 | 0.070 |
Why?
| | Fatigue | 2 | 2024 | 363 | 0.070 |
Why?
| | Radiation Dosage | 1 | 2010 | 193 | 0.070 |
Why?
| | Multivariate Analysis | 5 | 2012 | 1537 | 0.070 |
Why?
| | Marijuana Abuse | 1 | 2011 | 210 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2008 | 46 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2019 | 2033 | 0.070 |
Why?
| | Neurons | 2 | 2009 | 1639 | 0.070 |
Why?
| | Treatment Failure | 2 | 2024 | 365 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2446 | 0.070 |
Why?
| | Amygdala | 1 | 2009 | 198 | 0.070 |
Why?
| | Vancomycin Resistance | 1 | 2007 | 16 | 0.070 |
Why?
| | Gases | 1 | 1988 | 53 | 0.070 |
Why?
| | Fluorescein Angiography | 3 | 1996 | 190 | 0.070 |
Why?
| | Down-Regulation | 2 | 2007 | 616 | 0.070 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2008 | 79 | 0.070 |
Why?
| | Ophthalmoplegia | 1 | 1987 | 13 | 0.070 |
Why?
| | Enterococcus | 1 | 2007 | 22 | 0.070 |
Why?
| | Germinal Center | 1 | 2008 | 67 | 0.070 |
Why?
| | Torticollis | 1 | 1987 | 17 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 3070 | 0.070 |
Why?
| | Cytarabine | 3 | 2017 | 66 | 0.070 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2007 | 28 | 0.060 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 28 | 0.060 |
Why?
| | Models, Neurological | 1 | 2009 | 250 | 0.060 |
Why?
| | Rhinoplasty | 1 | 2008 | 39 | 0.060 |
Why?
| | Logistic Models | 4 | 2018 | 2114 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2008 | 112 | 0.060 |
Why?
| | Carrier State | 1 | 2007 | 79 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 2 | 2022 | 11 | 0.060 |
Why?
| | Temporal Lobe | 2 | 2022 | 103 | 0.060 |
Why?
| | Emotions | 2 | 2023 | 578 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2012 | 1705 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 400 | 0.060 |
Why?
| | Atrial Fibrillation | 1 | 2013 | 555 | 0.060 |
Why?
| | Ki-1 Antigen | 1 | 2006 | 7 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 1987 | 83 | 0.060 |
Why?
| | Flow Cytometry | 4 | 2015 | 1154 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 454 | 0.060 |
Why?
| | Prosthesis Implantation | 1 | 2008 | 154 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1501 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2021 | 288 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2006 | 54 | 0.060 |
Why?
| | Seat Belts | 1 | 1986 | 23 | 0.060 |
Why?
| | Eye | 1 | 2007 | 110 | 0.060 |
Why?
| | Quality of Life | 3 | 2023 | 3183 | 0.060 |
Why?
| | Behavior, Animal | 1 | 2009 | 521 | 0.060 |
Why?
| | Reproducibility of Results | 4 | 2015 | 3414 | 0.060 |
Why?
| | ROC Curve | 2 | 2023 | 618 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 2 | 2010 | 419 | 0.060 |
Why?
| | Cerebral Cortex | 1 | 2009 | 470 | 0.060 |
Why?
| | Lymphocyte Depletion | 1 | 2006 | 133 | 0.060 |
Why?
| | Anemia | 2 | 2018 | 189 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2026 | 139 | 0.060 |
Why?
| | Signal Transduction | 2 | 2010 | 5185 | 0.060 |
Why?
| | Pyridines | 1 | 2009 | 603 | 0.060 |
Why?
| | Isoquinolines | 1 | 2025 | 44 | 0.060 |
Why?
| | Melanoma | 2 | 1989 | 757 | 0.060 |
Why?
| | Retreatment | 2 | 2017 | 77 | 0.060 |
Why?
| | Amyloid | 1 | 2006 | 90 | 0.050 |
Why?
| | Risk Assessment | 4 | 2018 | 3729 | 0.050 |
Why?
| | Cross Infection | 1 | 2007 | 263 | 0.050 |
Why?
| | Pregnanolone | 1 | 2005 | 34 | 0.050 |
Why?
| | Neoplasm Grading | 2 | 2018 | 310 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 87 | 0.050 |
Why?
| | Cisplatin | 2 | 2022 | 339 | 0.050 |
Why?
| | Cognition | 2 | 2024 | 1263 | 0.050 |
Why?
| | Thiophenes | 1 | 2025 | 121 | 0.050 |
Why?
| | Algorithms | 1 | 2012 | 1844 | 0.050 |
Why?
| | Vitrectomy | 2 | 2013 | 73 | 0.050 |
Why?
| | Glaucoma | 1 | 1987 | 247 | 0.050 |
Why?
| | Aminopterin | 1 | 2024 | 3 | 0.050 |
Why?
| | Regression Analysis | 1 | 2006 | 998 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 539 | 0.050 |
Why?
| | Proteins | 1 | 2010 | 1016 | 0.050 |
Why?
| | Apoptosis | 2 | 2015 | 2397 | 0.050 |
Why?
| | Biopsy | 2 | 2019 | 1079 | 0.050 |
Why?
| | Area Under Curve | 2 | 2017 | 329 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2024 | 133 | 0.050 |
Why?
| | Acute Disease | 1 | 2026 | 1029 | 0.050 |
Why?
| | Anger | 1 | 2023 | 60 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2023 | 220 | 0.050 |
Why?
| | Lactate Dehydrogenases | 1 | 2022 | 6 | 0.050 |
Why?
| | Risk | 3 | 2010 | 911 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2017 | 427 | 0.050 |
Why?
| | Thymidylate Synthase | 1 | 2002 | 13 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 379 | 0.050 |
Why?
| | Creatine Kinase | 1 | 2022 | 72 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2007 | 3523 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 727 | 0.040 |
Why?
| | Body Weight | 2 | 2021 | 968 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2591 | 0.040 |
Why?
| | Organ Size | 2 | 2014 | 461 | 0.040 |
Why?
| | Agraphia | 1 | 2021 | 1 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2002 | 117 | 0.040 |
Why?
| | Hematologic Diseases | 2 | 2014 | 66 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2013 | 113 | 0.040 |
Why?
| | Pain | 3 | 2014 | 785 | 0.040 |
Why?
| | Confusion | 1 | 2021 | 30 | 0.040 |
Why?
| | Aphasia | 1 | 2021 | 24 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2009 | 960 | 0.040 |
Why?
| | Uric Acid | 1 | 2022 | 166 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2005 | 628 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1056 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 1484 | 0.040 |
Why?
| | Stem Cells | 1 | 2005 | 621 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 167 | 0.040 |
Why?
| | Glass | 2 | 2009 | 47 | 0.040 |
Why?
| | Galvanic Skin Response | 1 | 2020 | 26 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 205 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 323 | 0.040 |
Why?
| | Serum Albumin | 1 | 2021 | 144 | 0.040 |
Why?
| | Electroshock | 1 | 2020 | 145 | 0.040 |
Why?
| | Creatinine | 1 | 2022 | 509 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2022 | 342 | 0.040 |
Why?
| | Manitoba | 1 | 2000 | 4 | 0.040 |
Why?
| | Benzylamines | 2 | 2012 | 43 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 667 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 990 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 2013 | 407 | 0.040 |
Why?
| | Colonic Neoplasms | 1 | 2002 | 256 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3329 | 0.040 |
Why?
| | Vinblastine | 1 | 2019 | 75 | 0.040 |
Why?
| | Dacarbazine | 1 | 2019 | 100 | 0.040 |
Why?
| | Vero Cells | 2 | 2010 | 84 | 0.040 |
Why?
| | Medication Errors | 1 | 2000 | 82 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2021 | 503 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 303 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 851 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2014 | 516 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 886 | 0.040 |
Why?
| | Gamma Rays | 1 | 2018 | 56 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2018 | 71 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2018 | 198 | 0.030 |
Why?
| | Aging | 1 | 2009 | 1938 | 0.030 |
Why?
| | Blotting, Western | 2 | 2015 | 1161 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 119 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2010 | 524 | 0.030 |
Why?
| | Anthracyclines | 1 | 2018 | 49 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1327 | 0.030 |
Why?
| | Bleomycin | 1 | 2019 | 253 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2002 | 532 | 0.030 |
Why?
| | Seizures | 1 | 2022 | 477 | 0.030 |
Why?
| | Nursing Homes | 1 | 2000 | 173 | 0.030 |
Why?
| | Bendamustine Hydrochloride | 1 | 2017 | 17 | 0.030 |
Why?
| | Water Movements | 1 | 2017 | 30 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 337 | 0.030 |
Why?
| | Plasma Exchange | 1 | 2017 | 18 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 66 | 0.030 |
Why?
| | Etoposide | 2 | 2008 | 168 | 0.030 |
Why?
| | Infant | 3 | 2024 | 10023 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2018 | 281 | 0.030 |
Why?
| | Rain | 1 | 2017 | 49 | 0.030 |
Why?
| | Cell Count | 2 | 2009 | 320 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2019 | 0.030 |
Why?
| | Animals | 8 | 2015 | 37948 | 0.030 |
Why?
| | Cell Separation | 2 | 2010 | 303 | 0.030 |
Why?
| | Green Fluorescent Proteins | 2 | 2010 | 407 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2017 | 100 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2011 | 751 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 161 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 915 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2011 | 779 | 0.030 |
Why?
| | Neutropenia | 1 | 2017 | 155 | 0.030 |
Why?
| | Blood-Retinal Barrier | 1 | 1996 | 13 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 401 | 0.030 |
Why?
| | Retina | 1 | 2018 | 319 | 0.030 |
Why?
| | von Hippel-Lindau Disease | 1 | 1996 | 12 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2017 | 332 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1996 | 89 | 0.030 |
Why?
| | Registries | 2 | 2017 | 2392 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 427 | 0.030 |
Why?
| | Functional Neuroimaging | 1 | 2015 | 60 | 0.030 |
Why?
| | Extracellular Space | 1 | 1996 | 119 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2018 | 578 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.030 |
Why?
| | Foot | 1 | 2016 | 101 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5870 | 0.030 |
Why?
| | Adenine | 1 | 2017 | 337 | 0.030 |
Why?
| | France | 1 | 2014 | 40 | 0.030 |
Why?
| | Ankle Joint | 1 | 2016 | 122 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1301 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1122 | 0.030 |
Why?
| | Clone Cells | 1 | 2014 | 263 | 0.030 |
Why?
| | Polyradiculoneuropathy | 1 | 2013 | 5 | 0.030 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2013 | 14 | 0.030 |
Why?
| | Mitral Valve Insufficiency | 1 | 2014 | 68 | 0.030 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 20 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 607 | 0.030 |
Why?
| | Guillain-Barre Syndrome | 1 | 2013 | 23 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 924 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2013 | 63 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 881 | 0.020 |
Why?
| | Immunoassay | 1 | 2014 | 105 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1046 | 0.020 |
Why?
| | Survival | 1 | 2013 | 38 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 334 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 197 | 0.020 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 496 | 0.020 |
Why?
| | Device Removal | 1 | 2014 | 142 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2013 | 318 | 0.020 |
Why?
| | Medical Records | 1 | 2013 | 191 | 0.020 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 129 | 0.020 |
Why?
| | Vision, Binocular | 1 | 1993 | 47 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2015 | 328 | 0.020 |
Why?
| | Plasmacytoma | 1 | 2012 | 19 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2011 | 1468 | 0.020 |
Why?
| | Brachytherapy | 1 | 2013 | 133 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1134 | 0.020 |
Why?
| | Horner Syndrome | 1 | 1992 | 7 | 0.020 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 197 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 122 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1129 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2014 | 217 | 0.020 |
Why?
| | Explosions | 1 | 1991 | 14 | 0.020 |
Why?
| | Hippocampus | 2 | 2009 | 966 | 0.020 |
Why?
| | Farnesyltranstransferase | 1 | 2011 | 21 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 221 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 341 | 0.020 |
Why?
| | Food Labeling | 1 | 1991 | 13 | 0.020 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2011 | 53 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2013 | 270 | 0.020 |
Why?
| | Immunologic Techniques | 1 | 2011 | 38 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2013 | 390 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1494 | 0.020 |
Why?
| | RNA Splicing Factors | 1 | 2011 | 66 | 0.020 |
Why?
| | Blood Viscosity | 1 | 2010 | 19 | 0.020 |
Why?
| | Psychometrics | 1 | 2015 | 731 | 0.020 |
Why?
| | Iowa | 1 | 2010 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1704 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2010 | 24 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 255 | 0.020 |
Why?
| | Gastrointestinal Tract | 1 | 2013 | 207 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2010 | 55 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2010 | 4110 | 0.020 |
Why?
| | Prostaglandin Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1044 | 0.020 |
Why?
| | Silicon | 1 | 2010 | 21 | 0.020 |
Why?
| | Early Medical Intervention | 1 | 2010 | 61 | 0.020 |
Why?
| | Frontal Lobe | 1 | 2011 | 159 | 0.020 |
Why?
| | Transplantation Chimera | 1 | 2010 | 55 | 0.020 |
Why?
| | Syk Kinase | 1 | 2009 | 19 | 0.020 |
Why?
| | Exons | 1 | 2011 | 362 | 0.020 |
Why?
| | Cannabinoid Receptor Antagonists | 1 | 2009 | 1 | 0.020 |
Why?
| | Receptors, Cannabinoid | 1 | 2009 | 14 | 0.020 |
Why?
| | Accidents, Home | 1 | 2009 | 33 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2009 | 78 | 0.020 |
Why?
| | Administration, Topical | 1 | 1990 | 152 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2010 | 124 | 0.020 |
Why?
| | Boston | 1 | 2009 | 92 | 0.020 |
Why?
| | Ophthalmic Solutions | 1 | 1990 | 79 | 0.020 |
Why?
| | Medulla Oblongata | 1 | 2009 | 37 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2010 | 335 | 0.020 |
Why?
| | Mice, SCID | 1 | 2010 | 368 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2870 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2010 | 284 | 0.020 |
Why?
| | Periaqueductal Gray | 1 | 2009 | 37 | 0.020 |
Why?
| | Formaldehyde | 1 | 2009 | 64 | 0.020 |
Why?
| | Lacerations | 1 | 2009 | 40 | 0.020 |
Why?
| | Cataract | 1 | 1992 | 212 | 0.020 |
Why?
| | Endophthalmitis | 1 | 1989 | 46 | 0.020 |
Why?
| | Random Allocation | 1 | 1990 | 366 | 0.020 |
Why?
| | White Matter | 1 | 2011 | 153 | 0.020 |
Why?
| | Tumor Burden | 1 | 2010 | 324 | 0.020 |
Why?
| | Macular Edema | 1 | 1989 | 49 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 2009 | 97 | 0.020 |
Why?
| | Vision Disorders | 1 | 1991 | 179 | 0.020 |
Why?
| | Morpholines | 1 | 2009 | 129 | 0.020 |
Why?
| | Aminopyridines | 1 | 2009 | 129 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 199 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2011 | 247 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 194 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2839 | 0.020 |
Why?
| | Rats | 2 | 2009 | 5570 | 0.020 |
Why?
| | Intraoperative Complications | 1 | 1990 | 157 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 306 | 0.020 |
Why?
| | Diarrhea | 1 | 2009 | 192 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2009 | 290 | 0.020 |
Why?
| | Sulfur Hexafluoride | 1 | 1988 | 2 | 0.020 |
Why?
| | Prednisolone | 1 | 1988 | 66 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 444 | 0.020 |
Why?
| | Mucositis | 1 | 2008 | 20 | 0.020 |
Why?
| | Foreign Bodies | 1 | 2009 | 110 | 0.020 |
Why?
| | Methods | 1 | 1988 | 68 | 0.020 |
Why?
| | Hot Temperature | 1 | 1991 | 410 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1207 | 0.020 |
Why?
| | Orbital Diseases | 1 | 1988 | 37 | 0.020 |
Why?
| | Blindness | 1 | 1988 | 51 | 0.020 |
Why?
| | Air | 1 | 1988 | 45 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2008 | 79 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 527 | 0.020 |
Why?
| | Polyethylenes | 1 | 2008 | 12 | 0.020 |
Why?
| | Silicones | 1 | 2008 | 31 | 0.020 |
Why?
| | Vasculitis | 1 | 1988 | 69 | 0.020 |
Why?
| | Polytetrafluoroethylene | 1 | 2008 | 24 | 0.020 |
Why?
| | Purine-Nucleoside Phosphorylase | 1 | 2007 | 6 | 0.020 |
Why?
| | Membrane Cofactor Protein | 1 | 2007 | 14 | 0.020 |
Why?
| | Pneumonia | 1 | 2014 | 629 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2008 | 191 | 0.020 |
Why?
| | Vitreous Hemorrhage | 1 | 1987 | 10 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2010 | 572 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 820 | 0.020 |
Why?
| | Timolol | 1 | 1987 | 14 | 0.020 |
Why?
| | Pilocarpine | 1 | 1987 | 16 | 0.020 |
Why?
| | Ifosfamide | 1 | 2007 | 39 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2008 | 154 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2010 | 6399 | 0.020 |
Why?
| | Gene Rearrangement | 1 | 2008 | 155 | 0.020 |
Why?
| | Drug Therapy | 1 | 2007 | 80 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2010 | 501 | 0.020 |
Why?
| | Prodrugs | 1 | 2007 | 52 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 480 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 565 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 925 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 461 | 0.020 |
Why?
| | Pain Measurement | 1 | 2009 | 554 | 0.020 |
Why?
| | Birth Weight | 1 | 2010 | 506 | 0.020 |
Why?
| | Carboplatin | 1 | 2007 | 161 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 120 | 0.020 |
Why?
| | Trabeculectomy | 1 | 1987 | 75 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2006 | 47 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2008 | 141 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 1989 | 691 | 0.020 |
Why?
| | Legislation as Topic | 1 | 1986 | 5 | 0.020 |
Why?
| | Gestational Age | 1 | 2010 | 980 | 0.020 |
Why?
| | Injections | 1 | 2007 | 197 | 0.020 |
Why?
| | Immunocompetence | 1 | 2006 | 46 | 0.010 |
Why?
| | Enteral Nutrition | 1 | 2008 | 217 | 0.010 |
Why?
| | Mice | 3 | 2010 | 18261 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 2006 | 89 | 0.010 |
Why?
| | Choroid Neoplasms | 1 | 1986 | 9 | 0.010 |
Why?
| | Comorbidity | 1 | 2011 | 1652 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3147 | 0.010 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 423 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 1988 | 494 | 0.010 |
Why?
| | Rabbits | 1 | 2007 | 651 | 0.010 |
Why?
| | Gene Silencing | 1 | 2006 | 202 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 581 | 0.010 |
Why?
| | Tritium | 1 | 2005 | 68 | 0.010 |
Why?
| | Myelin Basic Protein | 1 | 2005 | 44 | 0.010 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.010 |
Why?
| | Nestin | 1 | 2005 | 19 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 2005 | 77 | 0.010 |
Why?
| | Intermediate Filament Proteins | 1 | 2005 | 57 | 0.010 |
Why?
| | Pregnancy | 2 | 2010 | 7122 | 0.010 |
Why?
| | Accidents, Traffic | 1 | 1986 | 193 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 473 | 0.010 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2005 | 125 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1374 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2006 | 372 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 232 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2005 | 195 | 0.010 |
Why?
| | Software | 1 | 2009 | 695 | 0.010 |
Why?
| | Cannabis | 1 | 2011 | 509 | 0.010 |
Why?
| | Adenoviridae Infections | 3 | 1958 | 20 | 0.010 |
Why?
| | Infant, Premature | 1 | 2008 | 614 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2008 | 436 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 973 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2184 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1339 | 0.010 |
Why?
| | Bed Rest | 1 | 1981 | 14 | 0.010 |
Why?
| | Pediatrics | 1 | 2010 | 1121 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2002 | 105 | 0.010 |
Why?
| | Immobilization | 1 | 1981 | 53 | 0.010 |
Why?
| | Recovery of Function | 1 | 2006 | 715 | 0.010 |
Why?
| | Joints | 1 | 1982 | 107 | 0.010 |
Why?
| | Bupivacaine | 1 | 1981 | 40 | 0.010 |
Why?
| | Colectomy | 1 | 2002 | 106 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 590 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4539 | 0.010 |
Why?
| | Hypertension | 1 | 2009 | 1262 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1981 | 86 | 0.010 |
Why?
| | Suture Techniques | 1 | 1981 | 137 | 0.010 |
Why?
| | Adenoviridae | 2 | 1958 | 199 | 0.010 |
Why?
| | Light Coagulation | 1 | 1980 | 10 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1476 | 0.010 |
Why?
| | Movement | 1 | 1982 | 295 | 0.010 |
Why?
| | HeLa Cells | 2 | 1958 | 632 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2521 | 0.010 |
Why?
| | Preoperative Care | 1 | 1981 | 379 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 2325 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1980 | 199 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2815 | 0.010 |
Why?
| | Cryotherapy | 1 | 1996 | 21 | 0.010 |
Why?
| | Laser Coagulation | 1 | 1996 | 79 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2005 | 5967 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 1982 | 1076 | 0.010 |
Why?
| | Polyarteritis Nodosa | 1 | 1988 | 11 | 0.000 |
Why?
| | Virus Diseases | 2 | 1956 | 218 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1988 | 597 | 0.000 |
Why?
| | Hand | 1 | 1982 | 161 | 0.000 |
Why?
| | Adenovirus Vaccines | 1 | 1958 | 2 | 0.000 |
Why?
| | Models, Biological | 1 | 1986 | 1811 | 0.000 |
Why?
| | Neutralization Tests | 1 | 1956 | 76 | 0.000 |
Why?
| | Antibody Formation | 1 | 1956 | 291 | 0.000 |
Why?
| | Viruses | 1 | 1956 | 166 | 0.000 |
Why?
| | Cell Culture Techniques | 1 | 1956 | 372 | 0.000 |
Why?
|
|
Johnston's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|